Ulcerative colitis (UC) is a chronic, immune-mediated condition characterized by ongoing inflammation of the large bowel. Symptomatic flares of UC are the result of mucosal inflammation, and patients experience diarrhea, usually with passage of blood, abdominal cramping, and tenesmus. Treatment is directed at reducing inflammation, initially through the use of anti-inflammatory agents such as 5-aminosalicylates[@R1] or corticosteroids administered orally or topically per rectum or immune-suppressing medications such as oral thiopurine agents and systemically delivered biologic agents such as anti-TNF antibodies,[@R2] and more recently the anti-α4β7 integrin antibody, vedolizumab.[@R3] Despite the availability of these therapies, treatment may be ineffective for many patients, and particularly systemically delivered immune-suppressing agents are associated with serious infections and other adverse effects. Additional therapies with novel mechanisms and improved safety profiles are needed.

Sirtuins (also called silent information regulator 2 \[Sir2\] proteins) are a class of proteins with important biological functions in organisms ranging from prokaryotes to eukaryotes.[@R4] They are NAD+-dependent deacetylases, with numerous well-defined substrates, that may play a role in a number of different diseases.[@R5]--[@R7] The mammalian sirtuins include a family of 7 recognized members, designated as SIRT1 through SIRT7,[@R4] and are implicated in various physiological roles in metabolism and inflammation.[@R8],[@R9] SIRT1 is best known for its role as a mediator in extending longevity through calorie restriction (CR),[@R10]--[@R12] but varieties of other beneficial metabolic and anti-inflammatory effects have been demonstrated.[@R13]--[@R17] Resveratrol, a component of red wine, is an SIRT1 activator, and has been shown to have metabolic and anti-inflammatory benefits, as well as an anticancer effect, and in addition may inhibit ischemic injury.[@R18]--[@R28] However, resveratrol is not a highly potent nor selective SIRT1 activator and, therefore, a variety of more potent SIRT1 activators have been developed to explore their potential therapeutic effect in diseases of aging and inflammation.[@R29]

To explore the effects of SIRT1 activation in UC, we assessed the safety, tolerability, colonic tissue exposure, and anti-inflammatory effects of 2 different doses of SRT2104, a SIRT1 activator, in subjects with mild to moderate UC.

MATERIALS AND METHODS {#s1}
=====================

Study Subjects {#s1-1}
--------------

Men and women aged 18 to 75 with mild to moderately active UC as evidenced by Mayo score[@R1] 6 to 10 (inclusive) with rectal bleeding score \>1, endoscopy score between 2 and 3 (inclusive), and physician\'s rating of disease activity \<3 at day 5 were enrolled. Subjects had confirmed diagnosis of UC for at least 3 months before the screening visit and colonic inflammation extending proximal to the rectum (ie, \>15 cm in extent) on baseline sigmoidoscopy at day 5. Subjects with infectious colitis as evidenced by positive stool culture for enteric pathogens or positive stool *Clostridium difficile* cytotoxin assay at visit 1 were excluded, and other significant medical disorders (respiratory, cardiovascular, renal or liver impairment, or hemoglobin less than 8.5 g/dL at visit 1) were excluded, as were subjects with flat or unresected raised colonic dysplasia. Treatment with oral aminosalicylates at doses ≤4.8 g per day was permitted if they were begun at least 4 weeks before study day 5. Rectal aminosalicylates at any dose within 2 weeks of study day 5, systemic or rectal corticosteroids within 4 weeks of study day 5, TNFα inhibitors or other biologics within 2 months before study day 5, or thiopurine agents initiated within 3 months before study day 5, or if changed in terms of dose within 3 months before study day 5 were not permitted. Previous participation in a clinical trial and treatment with a study drug within 3 months before visit 1 was also an exclusion factor.

Study Design {#s1-2}
------------

This study was conducted as a parallel group randomized, double-blind, study using 2 doses of SRT2104 (50 and 500 mg) at 13 centers in the United States. The first subject visit occurred on February 13, 2012, and the final visit on March 18, 2013. The clinical research was reviewed and approved by GSKs internal review panels and by both regional and local institutional review boards for each participating study site.

There was a screening period, an 8-week treatment period with 3 on-treatment visits (days 1, 28, and 56), and a follow-up visit (day 70), and phone follow-ups on days 14 and 42 to assess adverse events (AEs), as well as to complete the Simple Clinical Colitis Activity Index (SCCAI) score[@R30] and the partial Mayo score.[@R31]

Eligible subjects were randomized in a 1:1 ratio at visit 2 (day 5) to either 50 mg or 500 mg SRT2104 according to a computer-generated randomization schedule with no stratification; investigators and evaluators were blinded to treatment assignment factors.

Subjects received SRT2104 by mouth once daily from day 1 through day 56 (8 weeks). AEs were monitored from visit 2 (day 5) through the follow-up visit (day 70). Physical examinations findings, vital signs, clinical laboratory results (hematology, chemistry, urinalysis), and electrocardiograms were assessed at periodic intervals through day 70 and reviewed by an Internal Safety Review Committee. Two flexible sigmoidoscopies and colon biopsies were performed, 1 on day 5 (±2 days), before randomization, and 1 on day 56, to assess tissue levels of SRT2104, changes in UC histopathology scores and effects of SRT2104 on histologic markers of inflammation. Endoscopic scoring of UC lesions and the Mayo score were also assessed at both time points. Histopathologic specimens were paired for each subject and were analyzed by an independent pathologist who was blinded to dose of SRT2104 and to the time point the specimen was obtained (i.e., pre- or post-study drug exposure). Similarly, endoscopies were recorded; paired recordings were interpreted by an independent assessor who was blinded to the dose administered and time point. The SCCAI score and partial Mayo score were conducted at all study visits to evaluate the effect of SRT2104 on clinical signs and symptoms of UC. Blood was obtained on day 56 for the assessment of SRT2104 concentration.

Subjects who prematurely discontinued from the study completed day 56 assessments at the time of discontinuation pending discussion with the medical monitor. All subjects, including those who discontinued early, were asked to return for a safety follow-up visit approximately 14 days after their last visit.

Study Evaluations {#s1-3}
-----------------

The primary clinical end points were colonic exposure levels, safety, and tolerability. Safety evaluations were based on the incidence, severity, and type of AEs and clinically significant changes in the subject\'s vital signs, electrocardiogram, and clinical laboratory results during the course of the study. Safety variables were listed by treatment group, 50 mg or 500 mg SRT2104. SRT2104 drug levels as measured in colonic tissue samples were a key primary end point apart from safety and tolerability assessments. The secondary end points included response and complete remission rates based on changes in endoscopic assessment scores from baseline (day 5) to day 56, response and complete remission rates based on Mayo scores and partial Mayo scores from baseline (day 5) to day 56, mean change in Mayo scores, response and complete remission rates based on changes in SCCAI scores from baseline (day 5) to days, 28, and 56, mean changes in SCCAI sores, changes in fecal calprotectin from visit 1 to day 56, and changes in histopathologic scores from baseline (day 5) to day 56. In addition, a blood sample was collected on day 56 at the time of colon biopsy for the assessment of SRT2104 plasma concentration. Exploratory end points included biomarker changes in tissue from day 5 to day 56. Colon tissue samples were collected for exploratory biomarkers including, but not limited to, gene expression and cytokines. Blood was collected for exploratory biomarkers including, but not limited to, various proinflammatory cytokines. Exposure to study drug and reasons for discontinuation of study treatment were tabulated. In addition, the proportion of subjects who achieved response or remissions was tabulated. Exact methods were used to calculate response proportions and their confidence intervals (CIs). Change from baseline in Mayo and SCCAI scores were analyzed using a mixed model and included corresponding baseline score as covariate, subject as random effect, and treatment arm as a fixed effect. The mean change from baseline, difference between treatment groups, and the 90% CI of the difference were estimated.

Sample Size {#s1-4}
-----------

The primary focus of this study was to evaluate the safety, tolerability, and colonic tissue exposure in subjects with mild to moderate UC. Therefore, a formal sample size determination was not performed. Approximately, 24 subjects were planned for this study. Twelve subjects per arm would produce a 92% CI plus or minus 23% points when the response proportion is 60%. Also, with a sample size of 12 subjects per arm, the probability of observing at least 1 AE of a given type is 85.8% when the actual probability of this given AE is 15%.

Statistical Analysis {#s1-5}
--------------------

The safety data were summarized and listed by treatment group; for the pharmacokinetic data, the plasma and colon tissue concentrations were listed by treatment group and descriptively summarized without statistical analyses. For the clinical activity/pharmacodynamic analyses, no formal hypothesis was tested. The proportion of subjects who achieved response or remission based on the Mayo, endoscopy (independent assessment) and SCCAI scorings[@R32] were tabulated with a 95% CI.

Mean change from baseline/percent change from baseline to day 56 for Mayo, histology (Geboes),[@R33] and SCCAI scores were summarized descriptively by treatment group. Similarly, a change in fecal calprotectin from day 1 (day 21 to 4) to day 56 was descriptively summarized by treatment group and visit. A Mayo score response was defined as a reduction from baseline in Mayo score of either ≥3 and a 30% reduction from baseline and either a decrease in rectal bleeding subscore of ≥1 or an absolute rectal bleeding score ≤1. A Mayo score remission was defined as Mayo score ≤2 and no subscore \>1. An endoscopic response was defined as reduction from baseline in endoscopy score ≥1. An endoscopic remission was defined as an endoscopy score 0. SCCAI clinical response was defined as a reduction from baseline in SCCAI score ≥2 and clinical remission was defined as an SCCAI score ≤3.

The change from baseline and differences between treatment arms in Mayo and SCCAI scores were analyzed using a mixed model and included corresponding baseline score as covariate, subject as random effect, and treatment arm as a fixed effect. The mean change from baseline in histology, Mayo, and SCCAI at day 56 were estimated. A similar analysis was performed to compare the endoscopic score/Mayo score by the central reviewer against what the on-site investigator recorded. Distributional assumptions underlying the statistical analyses were assessed by visual inspection of residual plots. Normality was examined by normal probability plots, whereas homogeneity of variance was assessed by plotting the residuals against the predicted values for the model. The proportion of subjects who fell into different category within each item with respect to Mayo/SCCAI/histology scales was summarized by treatment and visit.

Biomarker analyses the changes in tissue biomarkers from day 5 to day 56 were summarized using descriptive statistics. Raw data change from baseline for blood biomarker end points were summarized descriptively, graphically presented, and listed by visit and each treatment group.

For gene expression microarray analysis, the colon samples obtained on day 5 and day 56 were hybridized to Affymetrix GeneChip HG-U133A-v2 and differential gene expression analysis and cluster analysis were performed.

Ethical Conduct of the Study {#s1-6}
----------------------------

This study was conducted in accordance with the ethical principles of the Declaration of Helsinki (version October, 2008) and the relevant regulations under 21 CFR parts 312, 50, and 56. A signed informed consent was obtained from each patient before performing any study related procedures. The study protocol and ICF were approved by institutional review boards of each participating study site. The first subject visited on February 13, 2012, and the last subject visit was March 18, 2013 ([clinicaltrials.gov](http://clinicaltrials.gov) NCT01453491).

RESULTS {#s2}
=======

A total of 56 subjects were screened of which 24 did not meet entry criteria, the remaining 32 subjects were randomized and 31 received study medication during this study (Fig. [1](#F1){ref-type="fig"}; Tables [1](#T1){ref-type="table"} and [2](#T2){ref-type="table"}).

![Consort diagram. One subject was excluded from analysis in the 50 mg/d group due to a major protocol violation.](ibd-22-607-g001){#F1}
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Summary of Number of Subjects Reporting AEs (Safety Population)
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Safety Results {#s2-1}
--------------

Overall, the frequency of subjects reporting any AE was similar between the 50 mg and 500 mg groups; however, there were proportionately more subjects with gastrointestinal AEs in the 500 mg group. Except for 2 cases of severe UC, all other AEs were mild to moderate in intensity. One subject in the 50 mg/d group was withdrawn due to a severe UC on day 19 that was considered serious but unrelated to the study medication by the investigator. This SAE was reported as resolving at study completion. One subject in the 500 mg/d was reported with a severe flare of UC, but not an SAE, resulting in withdrawal, which was reported as resolved at study completion.

In total, 4 subjects were withdrawn due to AEs. In addition to a subject withdrawn for UC, 1 subject in the 50 mg group was withdrawn on day 1 for abdominal pain upper (related) and fatigue (related) and another in the 500 mg was withdrawn on day 2 for photophobia (related-day 1), diarrhea (related-day 2), and headache (unrelated-day 2).

There were no clinically significant findings in the clinical laboratory values, vital signs, and electrocardiograms. There were isolated abnormal values in clinical chemistry and hematology laboratory values, but none was considered clinically significant.

Pharmacokinetic Results {#s2-2}
-----------------------

Plasma and colon tissue concentrations of SRT2104 for day 56 are summarized in Table [3](#T3){ref-type="table"}. The colonic tissue concentrations of SRT2104 achieved were approximately 140 to 160-fold the concentrations achieved in the plasma. In addition, there were dose-related increases in both the plasma and tissue concentrations when comparing 50 mg/d with 500 mg/d groups.

###### 

Summary of Plasma and Colon Tissue SRT2104 Concentration--Time Data
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Clinical Activity/Pharmacodynamic Results {#s2-3}
-----------------------------------------

The rates of remission and clinical response were low at both doses of SRT2104 administered based on the following assessment scores on day 56: Mayo, SCCAI, and endoscopy scores (4). Anti-inflammatory potential of SRT2104 was also not demonstrated based on histopathological scoring of colonic tissue biopsies.

A comparison of baseline and week 8 of cytokines were measured from repeated serial colon biopsies. The changes for the 50 and 500 mg/d during the treatment interval revealed changes, which were highly variable, and therefore their clinical significance was unclear (data not shown).

With respect to fecal calprotectin, changes in levels of measured biomarkers demonstrated reductions in both treatment groups (Table [4](#T4){ref-type="table"}). Baseline values of fecal calprotectin were comparable in both groups, a reduction was noted in fecal calprotectin levels from baseline to day 56 values in both treatment groups, and overall there was slightly larger decline in the 500 mg/d group compared with the 50 mg/d group. But at day 56, fecal calprotectin levels were still elevated relative to normal.

###### 

Summary of Fecal Calprotectin by Study Day (Microgram/Gram)
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Gene Expression Analysis Results {#s2-4}
--------------------------------

After QC analysis and preprocessing, a total of 33 microarray samples remained from 22 patients with day 5, day 56 data, or both were analyzed. No statistically significant gene expression changes were observed for day 5, day 56 comparisons, or for high-dose versus low-dose treatment comparisons. Cluster analysis of the top most variable genes (i.e., unbiased list of differentially regulated genes) showed significant enrichment of immune response--related biological pathways and processes, such as inflammatory response, cytokine activity, and leukocyte chemotaxis. Together, these results suggest relatively high heterogeneity between patient samples that precludes any conclusive findings. When limiting the analysis to samples from the 6 patients who responded to either treatment, a total of 36 genes had significantly altered expression levels (at least 2-fold upregulation or downregulation and unadjusted *P* value \<5%). Of these, 5 genes were downregulated posttreatment and 31 were upregulated. The top downregulated genes include *FOSB* and *GBP1*. The topmost upregulated genes include *DEFA6*, *HMGCS2*, *TM4SF20*, *UGT1A8*, and *DPP4*. Because of the low number of samples, these results require further validation.

DISCUSSION {#s3}
==========

One novel therapeutic approach to treating inflammatory bowel disease and other diseases of inflammation has come from the study of aging and CR. CR is a dietary regimen in which 30%--40% fewer calories than those required to maintain ideal body weight are consumed. It has been demonstrated that CR extends lifespan in lower organisms and mammals and improves a number of metabolic and inflammatory parameters.[@R10]--[@R12] As such, the molecular components of the aging pathways downstream of CR may provide relevant intervention points for the development of therapeutic drugs to treat inflammatory and metabolic disease.[@R8],[@R9]

SIRT1 is a member of the sirtuin family of NAD+-dependent deacetylases.[@R5]--[@R7] There are seven human sirtuins (SIRT1--7) with different subcellular compartmentalization and downstream targets.[@R4] SIRT1 is predominantly nuclear and is upregulated in tissues of calorically restricted animals.[@R34] The precise biological pathway whereby SIRT1 promotes the beneficial effects of CR is an area of intense study, but it seems that the ability of SIRT1 to interact and deacetylate PGC-1α is an important component.[@R35] PGC-1α controls energy metabolism and muscle function with an inhibitory role in proinflammatory cytokine production[@R36] and has been implicated as a key mediator of the effects of CR.[@R37] In addition, a number of other cellular substrates for SIRT1 have been identified, including NCoR, p300, NFκβ, FOXO, and p53.[@R13],[@R15],[@R17],[@R35],[@R38]--[@R43] For example, SIRT1 has been shown to physically interact with and deacetylate the RelA/p65 subunit of NFκβ, and thereby inhibit NFκβ-induced transcription,[@R43] which is involved in upregulation of proinflammatory cytokines such as TNF-α and IL-6. Furthermore, SIRT1 activators have been shown to inhibit TNF-α secretion in both in vitro[@R14],[@R44] and in vivo (Sirtris unpublished data) lipopolysaccharide (LPS)-induced cellular and animal models. A recent study of SRT2104 (a selective SIRT1 activator) in a human endotoxemia model of inflammation supports the preclinical findings. SRT2104 demonstrated an anti-inflammatory signal in this model, suppressing a number of cytokines and activation of coagulation in response to LPS administration[@R45] compared with placebo control. Through modulation of the activities of a number of proteins, SIRT1 regulates inflammation, cellular differentiation and survival, mitochondrial biogenesis, and glucose metabolism.[@R11],[@R15],[@R34],[@R46]

SRT2104 is a potent and selective small molecule activator of SIRT1. SIRT1 is known to deacetylate numerous substrates including the rel/p65 component of NFkB. Through deacetylation of this substrate, NFkB transcriptional activity is reduced, and thus there is a reduction in proinflammatory cytokine production. This is 1 mechanism whereby an SIRT1 activator, such as SRT2104, may exhibit anti-inflammatory activity. SRT2104 has been shown to be effective in vitro and in vivo in preclinical inflammatory studies, suppressing cytokine production in response to LPS and reducing disease activity in animal models including the DSS and TNBS models of IBD. In addition, SRT2104 was shown to reduce cytokine production in human volunteers in response to LPS administration. This earlier study confirmed the anti-inflammatory activity of SRT2104 in humans and supported studying the potential therapeutic use of SRT2104 in chronic inflammatory disorders such as UC. SRT2104, despite poor pharmacokinetics, also showed benefit in moderate to severe psoriasis patients treated for 12 weeks.[@R47]

In this clinical trial, overall SRT2104 was well tolerated, with the majority of study subjects completing the 8 weeks of treatment. The plasma exposures in UC patients are within the expected ranges (Table [3](#T3){ref-type="table"}) when compared with previous experience in healthy volunteers[@R29] but are low and with very high inter subject variability. Colon tissue concentrations achieved were 140- to 160-fold plasma concentrations (Table [3](#T3){ref-type="table"}). The response and remission rates based on Mayo score, endoscopy score by a blinded central reader, and the SCCAI scores (Table [5](#T5){ref-type="table"}) reveal, in general, no dose--response relationship and overall a disappointing clinical effect. Preclinical data with SRT2104 in animal models of UC had suggested that SRT2104 would have a primarily local effect in the colon with little systemic exposure. The data presented here suggest that this is not the case in patients with UC and that an effect on circulating leukocytes may be necessary. This is further evidenced by the modest response with respect to changes in fecal calprotectin, as fecal calprotectin levels were approximately 4-fold higher than the normal values after SRT2104 treatment. Normalization of fecal calprotectin can be achieved when highly effective therapies are used to treat UC.[@R48] In addition, the multiple cytokines measured from colon biopsy specimens revealed no clear and meaningful trends. Similarly, no conclusive findings were identified from the genetic expression analysis. The absence of a signal identified by the blinded central reader on endoscopy provides for no rationale for the continued development of SRT2104 in patients with UC. A limitation of this study was the absence of a placebo arm, a purposeful decision which was taken to facilitate patient recruitment. The decision unfortunately precludes evaluation of the magnitude of responses to SRT2104 relative to placebo responses. Thus, we are left to make comparisons of all measured responses compared with average historical responses, not taking into account placebo response rates.

###### 

Summary of Remission and Clinical Response
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CONCLUSIONS {#s4}
===========

The SIRT1 activator SRT2104 was well tolerated in a population of UC patients at doses of 50 and 500 mg/d, but the clinical response was disappointing and does not support any further development of SRT2104 in patients with UC.
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